PharmaTelevision - Gregory Moss Smith, Chief Executive Officer of Photonz explains their solution to the increasing demand for EPA which doesn’t involve fish oil

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Gregory Moss Smith, Chief Executive Officer of Photonz explains their solution to the increasing demand for EPA which doesn’t involve fish oil

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Gregory Moss-Smith, CEO of Photonz

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Photonz's EPA product

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe in Milan, in spring 2011. On this show I have Greg Moss Smith, who is Chief Executive of a New Zealand company called Photonz Corporation, welcome.

Gregory Moss Smith:

Hi Fintan.

Fintan Walton:

Greg, Photonz Corporation is a quite interesting corporation, it's in the area of manufacturing could you tell us the Photonzstory?

Gregory Moss Smith:

Well I think simply there is a growing demand for one of the omega-3 fatty acids a thing called EPA as an active ingredient in pharmaceuticals, and currently the only source for this high purity EPA is from fish oil which is a limited and fragile resource and the trick that Photonz has come up with is how to produce this high purity EPA by fermentation, so we just brew it like beer.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Gregory Moss Smith

Chief Executive Officer

Mr Gregory Moss Smith has 15 years of general management experience as a senior executive in the biopharmaceuticals sector and has been Chief Executive Officer of Photonz since late 2008. Previously part of the management team that integrated four companies to form Novozymes Biopharma, he served as Global Sales Director for the newly formed business. He was also responsible for establishing the company's worldwide sales organization based out of Cambridge, Massachusetts. Greg was previously the head of commercial operations of the successful Australian public biotechnology company, GroPep Ltd, where he built a team responsible for sales, marketing, business development, general legal and intellectual property management. He managed the company's commercial operations from 1997 through to the IPO in 2000 and its subsequent acquisition by Novozymes A/S in 2007. Greg's prior roles have included General Manager of Contract Manufacturing at GroPep Limited, Alternate Director of TGR Biosciences Pty Ltd, Director of the Cooperative Research Centre for Tissue Growth & Repair, Director & General Manager of Independent Biologics Ltd, Facilitator of the (NZ) National Science Strategy for Fisheries & Aquaculture and he was the founding manager of the Technology for Business Growth programmed at the Foundation for Research, Science & Technology (NZ).

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialization.

Photonz Corporation

Photonz Corporation is a biotechnology company producing the omega-3 fatty acid eicosapentaenoic acidEPA from marine microalgae. EPA is a critical ingredient in regulated pharmaceutical products addressing the cardiovascular disease drug market. Pharmaceuticals using EPA as an active ingredient are experiencing high growth. Previously, EPA could only be sourced from fish oil. Our product is designed to insure manufacturers in a multi-billion dollar market against the risk of reliance on natural fisheries as their main source of EPA.